Viracta Therapeutics (STU:RYIS) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)

Viracta Therapeutics Capex-to-Operating-Income Chart

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Capex-to-Operating-Income	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Viracta Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Viracta Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Capex-to-Operating-Income falls into.

Viracta Therapeutics Capex-to-Operating-Income Calculation

Viracta Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Viracta Therapeutics's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics  (STU:RYIS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Viracta Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description